Women with incurable breast cancer in England and Wales will not be offered a life-extending drug on the health service after ...

Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

The complaint was initiated by the Competition Commission and is lodged against Switzerland-based multinational healthcare ...

Barbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with ...

The Cancer Alliance intervenes in a landmark case against Roche, alleging excessive pricing of Trastuzumab, impacting thousands of South African women with breast cancer.

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or ...

Trastuzumab duocarmazine (T-Duo) improved progression-free survival to 7.0 months compared with 4.9 months with a physician’s choice in advanced human epidermal growth factor receptor 2 ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

These are some common ones and what they mean. Trastuzumab (Herceptin) was the first targeted therapy approved by the FDA for HER2+ breast cancer. It’s a type of biologic drug called a ...